SCHEMBL12470423

SCHEMBL12470423

COc1ccc(-c2nc3cc(C(F)(F)F)ccc3s2)cc1O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.66
SMN1; SMN2 Q16637 4/20 0.66
KDM4E B2RXH2 4/20 0.66
TP53 P04637 4/20 0.66
ALDH1A1 P00352 3/20 0.66
NPC1 O15118 3/20 0.66
KMT2A Q03164 3/20 0.66
HPGD P15428 2/20 0.66
MEN1 O00255 2/20 0.66
BLM P54132 2/20 0.66
HCRTR1 O43613 1/20 0.66
MAPK1 P28482 1/20 0.66
NPSR1 Q6W5P4 1/20 0.66
HSD17B10 Q99714 1/20 0.66
AHR P35869 1/20 0.56
RAB9A P51151 2/20 0.53
GLA P06280 2/20 0.53
GAA P10253 1/20 0.53
PPARG P37231 1/20 0.53
NCOA2 Q15596 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12471638 0.91 KDM4E (0.66) MAPTSMN1; SMN2KDM4ETP53ALDH1A1
SCHEMBL15455623 0.89 AHR (0.70) MAPTSMN1; SMN2KDM4ETP53ALDH1A1
SCHEMBL12470848 0.85 AHR (0.52) MAPTSMN1; SMN2KDM4ETP53ALDH1A1
SCHEMBL12470892 0.85 ILK (0.50) MAPTSMN1; SMN2KDM4ETP53ALDH1A1
SCHEMBL4803017 0.84 AHR (0.79) MAPTSMN1; SMN2KDM4ETP53ALDH1A1
SCHEMBL12470894 0.81 KDM4E (0.70) MAPTSMN1; SMN2KDM4ETP53ALDH1A1
SCHEMBL12471049 0.81 AHR (0.53) MAPTSMN1; SMN2KDM4EALDH1A1KMT2A
SCHEMBL12470870 0.81 KDM4E (0.59) MAPTSMN1; SMN2KDM4EALDH1A1NPC1
SCHEMBL15456386 0.81 MAPT (0.68) MAPTSMN1; SMN2KDM4ETP53ALDH1A1
SCHEMBL30504076 0.80 SMN1; SMN2 (1.00) MAPTSMN1; SMN2KDM4ETP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012108689-A2 NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREFOR 부산대학교 산학협력단 (KR) 2012-08-16 WO claimed
US-20150366776-A1 NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREOF PUSAN NAT UNIV IND COOP FOUND (KR) 2015-12-24 US disclosed
US-9155690-B2 Compound having skin-whitening, anti-oxidizing and PPAR activities and medical use thereof PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) 2015-10-13 US disclosed
US-8889881-B2 Compound having skin-whitening, anti-oxidizing and PPAR activities and medical use therefor Pusan National University Industry —University Cooperation Foundation (KR) 2014-11-18 US disclosed
US-20140037564-A1 NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREFOR Pusan National University Indusrtyuniversity (KR) 2014-02-06 US disclosed
WO-2012108689-A2 NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREFOR 부산대학교 산학협력단 (KR) 2012-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150366776-A1 NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREOF PPARG, PPARA, TYR MAPT 1956/4885SMN1; SMN2 3671/4885KDM4E 3430/4885
US-20140037564-A1 NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREFOR PPARG, PPARA, PPARD MAPT 2700/4885SMN1; SMN2 4087/4885KDM4E 3588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.